New York City, NY, 19 March 2020/24 Market Rports: It is estimated for the global aptamers market to reach USD 244.90 Million by 2021 at a CAGR of 17.86% during the forecast period of 2016 to 2021. A strong trend of R&D investments in biotechnology and pharmaceutical industries, patent expiration of the systematic evolution of ligands by exponential enrichment technology (SELEX), technological advancements, and the low cost and high efficiency of aptamers in binding to large molecules as compared to antibodies are driving the growth of the market during the forecast period.
Type, application, technology, and end-user are the segmentation for the market. DNA-based aptamers segment is leading the market during the forecast period. SELEX and other technologies are segmentation based on technology. Academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations (CROs), and other end users are the segmentation based on end-users. The academic and government research institutes segment is holding the largest share in the market.
Americas, Europe, Asia, and the Rest of the World (RoW) are the segmentation based on geography. Americas are expected to command the largest share of the global market. Europe is expected to register the highest growth due to increasing manufacturing in this region.